Abstract
Multiple myeloma is the most common plasma cell disorder, with an estimated 3,785 deaths in Japan in 2005. The mortality rate due to multiple myeloma is increasing every year and reached 5.93 per 100,000 in 2005 [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Statistics and information department, Minister’s secretariat, Ministry of Health, Labour and Welfare: Vital Statistics of Japan 2006. Health and Welfare Statistics Association.
Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208:1680–5.
Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832–42.
McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822–4.
Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–7.
Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.
Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–502.
Bataille R, Durie GM, Grenier J, Sany J. Prognostic factors and staging in multiple myeloma. A reappraisal. J Clin Oncol. 1986;4:80–7.
Greipp PR, San Miguel JF, Fonseca R, et al. Development of an International Prognostic Index (IPI) for myeloma: report of the International Myeloma Working Group. Hematol J. 2003;4 Suppl 1:S42–4.
Bataille R, Boccadoro M, Klein B, et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80:733–7.
Horger M, Claussen CD, Bross-Bach U, et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol. 2005;54:289–97.
Walker R, Barlogie B, Haessler J, et al. Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications. J Clin Oncol. 2007;25:1121–8.
Nosas-Garcia S, Moehler T, Wasser K, et al. Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. J Magn Reson Imaging. 2005;22:154–62.
Mulligan ME, Badros AZ. PET/CT and MR imaging in myeloma. Skeletal Radiol. 2007;36:5–16.
Breyer R, Mulligan M, Smith S, Line B, Badros A. Comparison of FDG PET/CT to other imaging modalities in myeloma. Skeletal Radiol. 2006;35:632–40.
Bredella M, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol. 2005;184:1199–204.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this chapter
Cite this chapter
Takenaka, K. (2013). Multiple Myeloma Surveillance Counterpoint: Japan. In: Johnson, F., et al. Patient Surveillance After Cancer Treatment. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-969-7_101
Download citation
DOI: https://doi.org/10.1007/978-1-60327-969-7_101
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-968-0
Online ISBN: 978-1-60327-969-7
eBook Packages: MedicineMedicine (R0)